Cargando…

Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?

Growing evidence indicates that clear cell renal cell carcinoma (ccRCC) is a metabolism-related disease. Changes in fatty acid (FA) and cholesterol metabolism play important roles in ccRCC development. As a nuclear transcription factor receptor, Liver X receptor (LXR) regulates a variety of key mole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Guangzhen, Wang, Qinglian, Xu, Yingkun, Li, Jianyi, Zhang, Hongge, Qi, Guanghui, Xia, Qinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538631/ https://www.ncbi.nlm.nih.gov/pubmed/31138790 http://dx.doi.org/10.1038/s41419-019-1654-6

Ejemplares similares

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
por: Griffett, Kristine, et al.
Publicado: (2023)

Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma
por: Li, Jianyi, et al.
Publicado: (2020)

TRIM33 Overexpression Inhibits the Progression of Clear Cell Renal Cell Carcinoma In Vivo and In Vitro
por: Xu, Yingkun, et al.
Publicado: (2020)

Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells
por: DiBlasio-Smith, Elizabeth A, et al.
Publicado: (2008)

A New Survival Model Based on ADAMTSs for Prognostic Prediction in Clear Cell Renal Cell Carcinoma
por: Wu, Guangzhen, et al.
Publicado: (2021)

Analysis of genomes and transcriptomes of clear cell renal cell carcinomas identifies mutations and gene expression changes in the TGF-beta pathway
por: Che, Xiangyu, et al.
Publicado: (2022)

Tripartite-motif family genes associated with cancer stem cells affect tumor progression and can assist in the clinical prognosis of kidney renal clear cell carcinoma
por: Wu, Guangzhen, et al.
Publicado: (2020)

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
por: Griffett, Kristine, et al.
Publicado: (2015)

A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma
por: Xu, Yingkun, et al.
Publicado: (2020)

Thrombomodulin activation driven by LXR agonist attenuates renal injury in diabetic nephropathy
por: Wang, Wei, et al.
Publicado: (2023)

Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells
por: Rough, James J, et al.
Publicado: (2010)

Identification of CPT1A as a Prognostic Biomarker and Potential Therapeutic Target for Kidney Renal Clear Cell Carcinoma and Establishment of a Risk Signature of CPT1A-Related Genes
por: Xu, Yingkun, et al.
Publicado: (2020)

Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches
por: Chen, Meimei, et al.
Publicado: (2018)

Identification of a New Prognostic Risk Signature of Clear Cell Renal Cell Carcinoma Based on N(6)-Methyladenosine RNA Methylation Regulators
por: Zhang, Yan, et al.
Publicado: (2021)

Approved LXR agonists exert unspecific effects on pancreatic β-cell function
por: Maczewsky, Jonas, et al.
Publicado: (2020)

LXR agonist improves peripheral neuropathy and modifies PNS immune cells in aged mice
por: Gavini, Chaitanya K., et al.
Publicado: (2022)

Glycolysis-Related Genes Serve as Potential Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma
por: Zhang, Yan, et al.
Publicado: (2021)

Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
por: Morin, Emily E., et al.
Publicado: (2020)

The liver X receptor agonist LXR 623 restricts flavivirus replication
por: Mlera, Luwanika, et al.
Publicado: (2021)

Flindissone, a Limonoid Isolated from Trichilia prieuriana, Is an LXR Agonist
por: Resetar, Mirta, et al.
Publicado: (2023)

Study on HOXBs of Clear Cell Renal Cell Carcinoma and Detection of New Molecular Target
por: Wu, Guangzhen, et al.
Publicado: (2021)

The Role of ERBB Signaling Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma and Establishing a Prognostic Risk Assessment Model for Patients
por: Wang, Zicheng, et al.
Publicado: (2022)

A new prognostic risk model based on autophagy-related genes in kidney renal clear cell carcinoma
por: Wu, Guangzhen, et al.
Publicado: (2021)

Reduction of fibrosis and immune suppressive cells in ErbB2-dependent tumorigenesis by an LXR agonist
por: Sheng, Gao, et al.
Publicado: (2021)

Establishment of a new prognostic risk model of MAPK pathway-related molecules in kidney renal clear cell carcinoma based on genomes and transcriptomes analysis
por: Zhang, Peizhi, et al.
Publicado: (2023)

Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis
por: Dragoljevic, Dragana, et al.
Publicado: (2023)

Using Genomic and Transcriptome Analyses to Identify the Role of the Oxidative Stress Pathway in Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance
por: Che, Xiangyu, et al.
Publicado: (2021)

Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance
por: Che, Xiangyu, et al.
Publicado: (2021)

A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma
por: Wu, Guangzhen, et al.
Publicado: (2020)

Development of a Novel Sphingolipid Signaling Pathway-Related Risk Assessment Model to Predict Prognosis in Kidney Renal Clear Cell Carcinoma
por: Sun, Yonghao, et al.
Publicado: (2022)

The mechanism of liver X receptor regulates the balance of glycoFAsynthesis and cholesterol synthesis in clear cell renal cell carcinoma
por: Wang, Qifei, et al.
Publicado: (2023)

ARL4C Regulates the Progression of Clear Cell Renal Cell Carcinoma by Affecting the Wnt/β-Catenin Signaling Pathway
por: Zhang, Peizhi, et al.
Publicado: (2022)

A New Survival Model Based on Cholesterol Biosynthesis-Related Genes for Prognostic Prediction in Clear Cell Renal Cell Carcinoma
por: Qi, Xiaochen, et al.
Publicado: (2021)

Insights From Liver‐Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR‐Agonist Pharmacodynamics in Humans
por: Minniti, Mirko E., et al.
Publicado: (2020)

Elucidation of Inverse Agonist Activity of Bilastine
por: Mizuguchi, Hiroyuki, et al.
Publicado: (2020)

LXR agonist inhibits inflammation through regulating MyD88 mRNA alternative splicing
por: Li, Ni, et al.
Publicado: (2022)

Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration
por: Wu, Guangzhen, et al.
Publicado: (2020)

Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data
por: Xu, Yingkun, et al.
Publicado: (2020)

Molecular dynamics of the ERRγ ligand-binding domain bound with agonist and inverse agonist
por: Sasidharan, Santanu, et al.
Publicado: (2023)

Identification of Selective ERRγ Inverse Agonists
por: Kim, Jina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9f70ienhkqhf60ftej88vto7ch